TATA健康(01255.HK)预计年度亏损1.5亿至1.7亿港元
格隆汇3月19日丨TATA健康(01255.HK)公告,公司预计截至2020年12月31日止年度录得归属母公司净亏损约1.5亿港元至约1.7亿港元。该年度的净亏损预期主要是由于(i)受到2019冠状病毒病疫情影响导致访港旅客持续减少以及消费者在全球经济下滑状况下更为审慎,这使得分别构成集团主要营收来源的鞋类及保健业务均受到严重冲击。预期于该年度集团总体销售收入与去年同期相比下滑约50%至60%;及(ii)集团于该年度将录得增加了资产减值损失,包括但不限于鞋类产品存货拨备、使用权资产及无形资产。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.